Loss of SH2B3 function could therefore modulate signals orchestrated by increased dose of DYRK1A through altered GSK-3β activity, although it remains to be determined whether this contributes to B-ALL. Here, GSK3B is linked to precursor B-cell acute lymphoblastic leukemia.